Wolverine Asset Management’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-22
Closed -$168 – 1810
2025
Q2
$168 Buy
+22
New +$343 ﹤0.01% 1561
2025
Q1
– Sell
-6
Closed -$220 – 1753
2024
Q4
$220 Sell
6
-172
-97% -$4.79K ﹤0.01% 1571
2024
Q3
$5.12K Sell
178
-49
-22% -$1.09K ﹤0.01% 1396
2024
Q2
$5.8K Buy
227
+58
+34% +$2.64K ﹤0.01% 1387
2024
Q1
$12.8K Sell
169
-63
-27% -$4.99K ﹤0.01% 1261
2023
Q4
$23.9K Sell
232
-468
-67% -$42K ﹤0.01% 1294
2023
Q3
$68.3K Sell
700
-25
-3% -$2.33K ﹤0.01% 1190
2023
Q2
$85K Buy
725
+420
+138% +$53.2K ﹤0.01% 1105
2023
Q1
$25.6K Sell
305
-36
-11% -$3.14K ﹤0.01% 1304
2022
Q4
$29K Buy
341
+308
+933% +$23.5K ﹤0.01% 1465
2022
Q3
$1K Hold
33
– – ﹤0.01% 2319
2022
Q2
$0 Hold
33
– – ﹤0.01% 2445
2022
Q1
$1K Buy
33
+24
+267% +$958 ﹤0.01% 2112
2021
Q4
$0 Buy
+9
New +$641 ﹤0.01% 2196
2021
Q2
– Sell
-154
Closed -$17K – 2379
2021
Q1
$17K Buy
+154
New +$25.7K ﹤0.01% 1789
2020
Q2
– Sell
-3,750
Closed -$789K – 1747
2020
Q1
$789K Buy
+3,750
New +$786K 0.01% 564

Other funds holding RVPH

Wolverine Asset Management's RVPH Position: Q3 2025 in Review

Wolverine Asset Management sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q3 2025, closing a stake of 22 shares — an estimated $168 sold.

Wolverine Asset Management first reported a position in RVPH in Q1 2020 and held it in 16 quarters. The position peaked at $789K in Q1 2020. 42 funds tracked by Wall St. Rank hold RVPH as of Q3 2025.

  • Wolverine Asset Management reported no remaining REVIVA PHARMA HLDGS INC position as of Q3 2025 after selling out during the quarter.
  • Wolverine Asset Management sold 22 REVIVA PHARMA HLDGS INC shares in Q3 2025, an estimated $168.
  • Wolverine Asset Management first reported a position in REVIVA PHARMA HLDGS INC in Q1 2020 and held it in 16 quarters.
  • Wolverine Asset Management's REVIVA PHARMA HLDGS INC position peaked at $789K in Q1 2020.
  • 42 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q3 2025.

Based on Wolverine Asset Management's 13F filing for Q3 2025, filed 28 Oct 2025.